SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is rapidly trending, generating significant discussion and amusement within the crypto community due to its provocative name. Investors are split between those embracing its meme potential, with calls for 'all-in' and 'generational holds,' and others who view it as a 'joke' or a sign of market absurdity. The coin's explicit name has sparked a wave of disbelief and humor, highlighting the speculative and often eccentric nature of some trending digital assets.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its recently strengthened balance sheet from a completed pension reversion, which is fueling investor excitement around its strategic pivot into pharmaceutical API manufacturing and advanced battery materials. The community actively anticipates significant government contracts for domestic pharma supply chains and a resurgence in film sales, leading many to expect a substantial revaluation and a 'Kodak moment' surge.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is actively trending as its dedicated community champions the crypto's deep ties to cannabis culture, positioning it as a 'plant-paced' project on the Solana blockchain. Enthusiasts consistently rally around the mantra of holding 'Bongterm' and proclaiming it to be 'like Bitcoin but way higher,' while also engaging in discussions about the broader utility and cultural significance of hemp within the ecosystem. This sustained community-driven narrative is the primary catalyst for its current momentum.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as activist investor Elliott Management has taken a significant stake, reportedly advocating for a new CEO, intensifying the focus on leadership changes ahead of the current CEO's departure. The community is also keenly awaiting a Supreme Court decision on tariffs, which many believe could significantly impact the stock and the broader retail sector, fueling discussions on LULU's valuation amidst strong holiday performance and international growth.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid a heated debate following conflicting analyst reports, with a recent downgrade from Morgan Stanley sparking strong community pushback. Many investors view KHC as a deeply undervalued defensive play with a substantial dividend, anticipating that the upcoming company split will unlock significant value despite current market skepticism and perceived manipulation by shorts. This sentiment suggests a broader rotation into consumer staples as a safe haven from overvalued sectors.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp (CNC) is trending amid heated debate over the potential extension of Affordable Care Act (ACA) subsidies and proposals by former President Trump to redirect healthcare funding directly to individuals. The community is divided, with some anticipating an extension to be bullish for managed care, while others fear significant policy changes could negatively impact insurers heavily exposed to government programs. This uncertainty is driving discussions around institutional accumulation versus retail selling, as the sector grapples with evolving political narratives.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending with strong community enthusiasm following its major partnership with World Liberty Financial, integrating USD1 for widespread payroll and card services. Investors are highly focused on this real-world utility, the impending launch of its Super App, and confirmed Stellar blockchain integration, with many anticipating significant growth as token supply approaches full circulation.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund (UNG) is experiencing extreme volatility, primarily fueled by rapidly shifting weather forecasts that have recently turned warmer, causing a sharp decline. Traders are sharply divided, with some anticipating a bounce on oversold conditions and long-term demand growth from sectors like AI, while others highlight the product's historical decay and perceived market manipulation.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors eagerly await updates from recent presentations and an upcoming video series featuring General Jack Keane, underscoring its pivotal role in national defense. The community is highly bullish on UAMY, recognizing it as the sole domestic antimony producer supplying the U.S. military. This positions the company as crucial in broader government initiatives to establish resilient critical mineral supply chains and reduce foreign dependence.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending following substantial contract wins, including a significant multi-year award from ICE for immigration monitoring and new correctional facility contracts in Florida. Investors are widely discussing the stock's deep undervaluation and strong tailwinds from anticipated increases in immigration enforcement, even as many express frustration with recent price action. This sentiment, combined with an ongoing share buyback program, is driving a "buy the dip" mentality amidst expectations for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial compares Bacillus Calmette-Guérin (BCG) therapy alone with BCG combined with ANKTIVA.</li><li>Preliminary analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve cancer patients.</li><li>ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.</li></ul>ImmunityBio, Inc. (IBRX) shares jumped 24% in premarket trading on Friday after the company reported a faster than expected enrollment for its QUILT-2.005 bladder cancer drug trial.The company said that enrollment has surpassed internal expectations and is now more than 85% complete, with full enrollment of the planned study population expected by the second quarter of 2026.&nbsp;Based on current progress, ImmunityBio plans to submit a biologics license application to the U.S. Food and Drug Administration (FDA) by the end of 2026.“We look forward to the final accrual of this important registrational randomized trial in patients with BCG-naïve non-muscle-invasive bladder cancer, which represents a substantial proportion of newly diagnosed bladder cancer cases. The interim analysis is encouraging and consistent with findings in the approved BCG-unresponsive setting, where the duration of complete response has exceeded 47 months,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.Based on current progress, ImmunityBio plans to submit a biologics license application to the FDA by the end of 2026.<h2 class="st-heading-2">What Is The Trial About?</h2>The QUILT-2.005 is a clinical trial for Bacillus Calmette-Guérin (BCG) naïve non-muscle-invasive bladder cancer (NMIBC) that compares standard BCG therapy alone versus BCG combined with ANKTIVA, an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.In 2023, the FDA requested an interim analysis of the randomized trial to evaluate the added benefit of ANKTIVA when combined with BCG, focusing on complete response rates and the durability of response versus BCG alone.The analysis showed that ANKTIVA plus BCG significantly extended the duration of complete response in BCG-naïve NMIBC patients. At six months, 85% of patients receiving the combination maintained a complete response, compared with 57% in the BCG-only group. At nine months, response rates were 84% with combination therapy versus 52% with BCG alone.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_3d2f27a76b.webp" alt="IBRX.jpg">One user was bullish about the company’s potential.<stembedurl>https://stocktwits.com/Amit18/message/642024906</stembedurl>Another user saw the stock as a long-term runner.<stembedurl>https://stocktwits.com/LeftyT/message/642025351</stembedurl>Over the past year, the stock has gained more than 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-set-for-all-time-high-morgan-stanley-boost/cmUlAaBR4B7">RKLB Stock Is On Track For Record Open – Here’s What’s Driving The Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today 

The company said that enrollment for its randomized registrational QUILT-2.005 trial has surpassed internal expectations and is now more than 85% complete.

 IBRX Stock Rallies As Its Bladder Cancer Study Nears Full Enrollment 

Equity

<ul class="summary-bullets"><li>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa.</li><li>The company will also partner with regional pharmaceutical firm BioPharma Cigalah.</li><li>Enrolment for the QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter.</li></ul>ImmunityBio, Inc. (IBRX) drew retail attention on Wednesday as the stock jumped 8% after the Saudi Food and Drug Authority approved ANKTIVA in combination with the BCG (Bacillus Calmette-Guérin) vaccine to treat adults with BCG-unresponsive non-muscle invasive bladder cancer.The approval marks a major regulatory milestone, adding to existing authorizations in the United States and the United Kingdom, as well as conditional approval in the European Union.“We are pleased to bring ANKTIVA to Saudi patients with NMIBC, who otherwise have no viable options but life-altering surgery,” said Rich Adcock, Chief Executive Officer, ImmunityBio.<h2 class="st-heading-2">ImmunityBio’s Expansion Plans</h2>ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North Africa. The company will also partner with regional pharmaceutical firm BioPharma Cigalah. Management cited the rising incidence of bladder and other cancers in the region as a key driver behind the strategy.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells.<h2 class="st-heading-2">ANKTIVA Developments</h2>Beyond bladder cancer, ANKTIVA is also drawing attention for its broader oncology potential. <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-surge-today/cmUXXCjR4Ig">Recent clinical data</a> from the QUILT-2.023 and QUILT-3.055 trials in non-small cell lung cancer (NSCLC) showed improved immune recovery and extended survival when ANKTIVA was combined with checkpoint inhibitors.Responding patients achieved a median survival of up to 21.1 months, significantly outperforming traditional chemotherapy outcomes.Meanwhile, enrolment for the company’s QUILT-2.005 study evaluating ANKTIVA with BCG in earlier-stage bladder cancer is expected to be completed by the second quarter (Q2) of 2026 and a potential biologics license application (BLA) by the end of the year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around ImmunityBio remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_1a3db9b5f3.webp" alt="IBRX.jpg">One user speculated that the approval could double the product revenue for the company.<stembedurl>https://stocktwits.com/Bc3345/message/641787673</stembedurl>One user sees the stock climb to $5 in the short term and $15-25 in the medium term.<stembedurl>https://stocktwits.com/AshvsEvilDead/message/64178170</stembedurl><a href="https://stocktwits.com/AshvsEvilDead/message/641781706">6</a>Over the past year, <a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> have risen around 21%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-clsk-stock-rising-premarket-texas-data-centre-deal/cmULgA7R4e0">CLSK Stock Receives Premarket Boost On Texas Data Center Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval

The approval in Saudi Arabia follows authorizations in the U.S. and the U.K., as well as a conditional approval in the European Union.

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

<ul class="summary-bullets"><li>The company said that responding patients lived longer overall, with a median survival of 16.2 months.</li><li>The data come from two clinical trials, evaluating 151 patients across first-line and later-line treatment settings.</li><li>ImmunityBio is now advancing its Phase 3 trial, it said.</li></ul>ImmunityBio Inc. (IBRX) stock caught retail attention on Tuesday after the company reported positive clinical results showing its immunotherapy ANKTIVA significantly boosts immune function and improves survival in non-small cell lung cancer (NSCLC) patients when combined with checkpoint inhibitors.The data come from two clinical trials, QUILT-2.023 and QUILT-3.055, evaluating 151 patients across first-line and later-line treatment settings.<a href="https://stocktwits.com/symbol/IBRX">IBRX shares</a> were up 12.4% at the time of writing. Retail chatter increased to ‘high’ on Stocktwits while sentiment shifted to ‘extremely bullish’ from ‘bullish’ a day earlier.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_72f59b2252.webp" alt="IBRX.jpg">One bullish user expects the U.S. Food and Drug Agency (FDA) to approve ANKTIVA for NSCLC and expand access broadly.<stembedurl>https://stocktwits.com/svertical1/message/641645369</stembedurl>Another user sees the benefits of a non-chemotherapy treatment.<stembedurl>https://stocktwits.com/Armymike1981/message/641633526</stembedurl><h2 class="st-heading-2">Outcome Of The Trials</h2>In the first-line QUILT-2.023 study, patients receiving ANKTIVA plus a checkpoint inhibitor showed a statistically significant and sustained increase in absolute lymphocyte count (small white blood cell) compared with checkpoint inhibitor therapy alone. In the second- and later-line QUILT-3.055 study, 77% of patients maintained or restored healthy lymphocyte levels, showing ANKTIVA’s role as a lymphocyte-stimulating agent.The company said that responding patients lived longer overall, with a median survival of 16.2 months, while those with stronger immune recovery had a median survival of 21.1 months, far exceeding historical results with standard chemotherapy.ImmunityBio is now advancing its Phase 3 trial, comparing ANKTIVA plus checkpoint inhibitors to docetaxel in second-line NSCLC, it added.“The results from these studies support a potential paradigm shift toward what we define as Immunotherapy 2.0, which is the coordinated activation of the innate immune system through natural killer cells and the adaptive immune system through T cells to restore immune competence and extend survival,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio.Over the past year, IBRX shares have gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-q4-revenue-beat-apple-card-reserve-hits-profit/cmUXEfbR44r">JPMorgan Beats Revenue Estimates In Q4 – A Record Quarter For Wealth Unit Offsets Apple Card Drag</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients

The company reported positive results with ANKTIVA, which boosted immune function and improved survival in NSCLC when combined with checkpoint inhibitors.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

<ul class="summary-bullets"><li>Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows.&nbsp;</li><li>Tradipitant previously failed in gastroparesis but is now under FDA review with labeling discussions underway.</li><li>Approval could open a motion-sickness market estimated at $670 million in 2025.</li></ul>Vanda Pharmaceuticals (VNDA) is facing a moment of reckoning as it awaits an FDA nod for its motion-sickness treatment candidate. After a so-so performance for much of the year, the&nbsp;<a href="https://stocktwits.com/symbol/VNDA">Vanda stock</a> rally kicked off in the middle of November and has been going strong ever since.&nbsp;Between Nov. 14 and Friday’s trading session, the stock has gained about 62%, wiping out the year's losses.<h2 class="st-heading-2">Binary Event Beckons</h2>More than 13 years after licensing NK-1R from Lilly (LLY) for a $1 million upfront payment—and over a year after the FDA rejected its application in gastroparesis—Vanda is once again knocking on the regulator’s door, this time seeking approval for motion sickness. Vand has since rechristened the drug candidate as tradipitant.&nbsp;Last September, the drug regulator issued a Complete Response Letter (CRL) to the new drug application (NDA) for tradipitant for treating symptoms of gastroparesis. A CRL is a letter stating that the agency will not approve a regulatory application in its current form.Reacting to the decision, Vanda said:<blockquote>“The CRL was conclusory in nature, generally disregarded the evidence provided and instead suggested that Vanda conduct additional studies with a design and duration inconsistent with the advice of key experts in the field and not appropriate based on the scientific understanding and natural course of the disorder.”</blockquote>Vanda has looked past the disappointment and is hoping for good news. Providing a regulatory update on tradipitant as a preventive treatment for motion sickness-induced vomiting in late November, Vanda stated that the Prescription Drug User Fee Act (PDUFA) target date of Dec. 30 for completion of the review remained unchanged. It also confirmed that the FDA recently issued comments on the proposed labeling and that labeling discussions have formally commenced. If approved, Vanda will have the distinction of delivering the first new pharmacologic treatment for motion sickness in over four decades.According to Mordor Intelligence, the total addressable opportunity for motion sickness is around $670 million in 2025. This is expected to grow at a 3.1% compounded annual growth rate (CAGR), reaching $781 million by 2030.Tradipitant earlier produced positive results in a study that evaluated it as a treatment option for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults.In other recent developments, Vanda announced in early December that the FDA had lifted the partial clinical hold on the tradipitant protocol, which had limited the doses that could be administered. This decision allows Vanda to extend clinical studies of tradipitant in motion sickness.In mid-December, the company said it had submitted a Biologics License Application (BLA) for imsidolimab to treat generalized pustular psoriasis (GPP). It expects to end the year with $260 million to $290 million in cash.&nbsp;Founded in 2003, Vanda focuses on new technologies, including genetics and genomics, for drug discovery, clinical trials, and commercial positioning. The company sells Hetlioz as a treatment for sleep-wake disorder, Fanapt, an antipsychotic medication, and Ponvory for relapsing multiple sclerosis. Vanda generates net product sales of $158.9 million for the first nine months of 2025, marking 9% year-over-year (YoY) growth.&nbsp;<h2 class="st-heading-2">Upcoming Catalysts</h2>Apart from the imminent FDA decision, the company has a slew of catalysts that can propel the stock higher if they pan out favorably. Key among the catalysts are:-FDA decision date for Feb. 21, 2026, for Bysanti (milsaperidone) NDA for bipolar I disorder and schizophrenia-Re-review of the supplemental NDA for Hetlioz for the treatment of jet lag disorder by Jan. 7, 2026<h2 class="st-heading-2">What Analysts and Retail Traders Feel About Vanda</h2>Initiating coverage of Vanda stock with a ‘Buy’ rating and a $11 price target in early November, B. Riley said Vanda is a commercial-stage turnaround story trading at a "historic discount,” the Fly reported. The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines,” the firm said.<img src="https://news.stocktwits-cdn.com/Vandas_Valuation_PS_png_bcec7dcc5c.webp" alt="Vandas_Valuation_PS.png">Source: Fiscal.aiOn Stocktwits, retail traders are ‘bullish’ about&nbsp;Vanda as of early Monday.<figure class="image"><img style="aspect-ratio:725/444;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_7_43_31_AM_png_814cfe36d5.webp" alt="Screenshot 2025-12-29 at 7.43.31 AM.png" width="725" height="444"></figure>&nbsp;A retail watcher was already bracing for $10+ level early this week,&nbsp;<a href="https://stocktwits.com/ms0632/message/640275096">anticipating</a> “good news.” Another user said that, irrespective of the FDA decision, the company has other sales and opportunities to limit downside. Citing “big upside potential,” they&nbsp;<a href="https://stocktwits.com/djacks/message/640216881">said</a> they added more shares.In premarket trading on Monday, the stock climbed over 4% to $7.35.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-outperformed-vs-nvidia-microsoft-ai-stocks-2025/cL75psZREDr">Palantir Crushed Nvidia, Microsoft And Most AI Stocks In 2025 — And Investors Didn’t Care About Valuation</a>

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock

Vanda’s shares have surged since mid-November ahead of a pivotal FDA decision on tradipitant for motion sickness, a binary event that could unlock a new market and drive further upside, with additional regulatory catalysts ahead.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a more reasonable valuation.</li><li>Moderna continues to struggle post-pandemic, with weak fundamentals, no new blockbusters, and higher regulatory scrutiny weighing on its pipeline.</li><li>Analysts see greater upside for Super Micro than Moderna, while retail sentiment remains cautious toward both stocks.</li></ul>Investing in heavily shorted stocks isn't for the faint-hearted. While they can offer meaningful upside, that potential comes with heightened volatility and elevated risk. More often than not, they are shorted for legitimate reasons. But if the sentiment flips, these stocks can deliver explosive gains. The most-shorted S&amp;P 500 list currently includes two names that won't surprise many investors.&nbsp;Moderna — the biopharma that, along with Pfizer, led the COVID-19 vaccine race — rode a historic wave of demand during the pandemic. But as the outbreak faded and vaccine sales collapsed, the company's fundamentals have come under pressure despite efforts to sustain momentum with second-generation and combination shots. The company is still searching for its next blockbuster therapy.Super Micro Computer, Inc. (SMCI), which rode the artificial intelligence mania, selling AI servers, was once touted as a promising opportunity. The company, however, ran into rough weather in 2024 amid accusations of accounting issues, delays in filing of financial reports, and&nbsp;attacks from short-sellers.Since peaking at $122.90 on March 8, 2024, the stock has traded broadly downward for the rest of the year. Super Micro's addition to the S&amp;P 500 provided a boost, but it failed to reignite the uptrend. Notably, the company was removed from the Nasdaq 100 just five months after its inclusion in the tech index.<h2 class="st-heading-2">Stock Returns This Year</h2>As Super Micro became compliant with the listing requirements for timely quarterly reporting, buyers returned to the stock. The<a href="https://stocktwits.com/symbol/SMCI">&nbsp;SMCI stock</a> also benefited from the company's new offerings involving Nvidia's newest high-performance chips and its positive long-term outlook. Its near-term underperformance raised concerns among investors.&nbsp;After rising through the first quarter, Super Micro's stock pulled back and hit a low in mid-November and has been consolidating since.<a href="https://stocktwits.com/symbol/MRNA">Moderna's stock</a> was on a steady downward trajectory this year, barring occasional consolidation moves.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_stock_returns_png_dd55f22501.webp" alt="MRNA-SMCI stock returns.png">Source: Koyfin<h2 class="st-heading-2">Elevated Short Bets&nbsp;</h2>According to Koyfin, the short interest for Super Micro peaked in April (19.60%) before reducing to 14.70% currently. Moderna's short interest, though off its May peak of 17.40%, has declined by less than one percentage point.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_short_interest_png_9af30dca45.webp" alt="MRNA-SMCI-short interest.png">Source: Koyfin<h2 class="st-heading-2">Time To Revisit?</h2>Super Micro now trades at a relatively reasonable valuation (in terms of the forward price-earnings (P/E) multiple versus the tech sector and its peak multiple).<img src="https://news.stocktwits-cdn.com/SMCI_Forward_PE_png_d98fc94770.webp" alt="SMCI_Forward_PE.png">Source: Fiscal.aiModerna, on the other hand, trades at a much higher price-to-sales (P/S) multiple than it did last July. Since Moderna is projected to report losses over the next year, the P/E ratio isn't applicable.<img src="https://news.stocktwits-cdn.com/MRNA_Forward_PS_png_794682e423.webp" alt="MRNA_Forward_PS.png">Source: Fiscal.aiAccording to Koyfin-compiled consensus analysts' stock price targets for the companies,&nbsp; estimates, Super Micro has an upside potential of 39% versus 23% for Moderna.&nbsp;Super Micro has an equal share of analysts who are bullish and neutral on the stock. Meanwhile, more analysts are on the sidelines of Moderna (15 of the 22 analysts covering the stock).On Stocktwits, retail traders are 'bearish' on Super Micro as of early Thursday, while Moderna elicited 'neutral' sentiment.For Super Micro, simmering AI bubble fears could remain an overhang on the stock. Still, if the company can execute its plans and leverage its partnership with Nvidia, the stock could see a reversal in fortunes. Moderna, meanwhile, remains a "show-me" story as it has to prove the mettle of the rest of its pipeline. Moderna also faces regulatory uncertainty as the FDA applies heightened scrutiny to new vaccines and therapeutics, adding another layer of risk to its pipeline.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/powell-didn-t-surprise-how-retail-traders-are-positioning-after-fed-s-rate-cut/cLIx7TYREn2">&nbsp;Powell Didn't Surprise — But Markets Might: How Retail Traders Are Positioning After Fed's Rate Cut</a>

 Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2025 in New York City. After losing over 400 points on the first day of December, the market began to recover with the Dow up over 120 points in morning trading. 

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze?

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF